F
Sorrento Therapeutics, Inc.
SRNE
$0.001
$0.000111.11%
E
Sell
3/14/2023Downgrade
Sorrento Therapeutics, Inc. (SRNEQ) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
Sorrento Therapeutics, Inc. (SRNEQ) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and valuation index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index and valuation index.
E
Sell
2/8/2023Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index, valuation index and total return index. EBIT declined 19.88% from -$91.88M to -$110.14M.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index, valuation index and total return index. EBIT declined 19.88% from -$91.88M to -$110.14M.
D
Sell
5/16/2022Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 05/04/2022.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 04/21/2022.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.4003 to -$0.4674, and EBIT declined 16.12% from -$90.26M to -$104.81M.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.4003 to -$0.4674, and EBIT declined 16.12% from -$90.26M to -$104.81M.
D
Sell
11/23/2021Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. Total revenue increased 125.58% from $5.78M to $13.03M, operating cash flow increased 21.4% from -$45.83M to -$36.02M, and earnings per share increased from -$0.5028 to -$0.4047.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. Total revenue increased 125.58% from $5.78M to $13.03M, operating cash flow increased 21.4% from -$45.83M to -$36.02M, and earnings per share increased from -$0.5028 to -$0.4047.
D
Sell
8/28/2019Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 8/28/2019 due to a decline in the volatility index and total return index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 8/28/2019 due to a decline in the volatility index and total return index.
D
Sell
8/13/2019Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 8/13/2019 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.8838 to -$0.4745, and total revenue increased 5.44% from $6.14M to $6.48M.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 8/13/2019 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.8838 to -$0.4745, and total revenue increased 5.44% from $6.14M to $6.48M.
D
Sell
5/16/2019Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 5/16/2019 due to a major decline in the total return index, growth index and efficiency index. Net income declined 117.11% from -$49.78M to -$108.07M, earnings per share declined from -$0.4136 to -$0.8838, and total revenue declined 11.34% from $6.93M to $6.14M.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 5/16/2019 due to a major decline in the total return index, growth index and efficiency index. Net income declined 117.11% from -$49.78M to -$108.07M, earnings per share declined from -$0.4136 to -$0.8838, and total revenue declined 11.34% from $6.93M to $6.14M.
D
Sell
8/14/2018Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 8/14/2018 due to a decline in the total return index, growth index and efficiency index. Net income declined 126.76% from -$32.57M to -$73.86M, earnings per share declined from -$0.3835 to -$0.7345, and total revenue declined 37.35% from $6.25M to $3.91M.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 8/14/2018 due to a decline in the total return index, growth index and efficiency index. Net income declined 126.76% from -$32.57M to -$73.86M, earnings per share declined from -$0.3835 to -$0.7345, and total revenue declined 37.35% from $6.25M to $3.91M.
D
Sell
5/29/2018Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D on 5/29/2018 due to an increase in the total return index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D on 5/29/2018 due to an increase in the total return index and volatility index.
D
Sell
5/11/2018Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 5/11/2018 due to a major decline in the growth index and efficiency index. EBIT declined 1,350.39% from -$1.4M to -$20.32M, net income declined 167.24% from $48.45M to -$32.57M, and earnings per share declined from $0.5792 to -$0.3835.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 5/11/2018 due to a major decline in the growth index and efficiency index. EBIT declined 1,350.39% from -$1.4M to -$20.32M, net income declined 167.24% from $48.45M to -$32.57M, and earnings per share declined from $0.5792 to -$0.3835.
D
Sell
5/10/2018Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 5/10/2018 due to a decline in the total return index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 5/10/2018 due to a decline in the total return index.
C
Hold
4/25/2018Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 4/25/2018 due to an increase in the total return index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 4/25/2018 due to an increase in the total return index.
D
Sell
4/9/2018Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 4/9/2018 due to a decline in the total return index, efficiency index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 4/9/2018 due to a decline in the total return index, efficiency index and volatility index.
C
Hold
3/22/2018Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 3/22/2018 due to an increase in the total return index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 3/22/2018 due to an increase in the total return index.
D
Sell
3/16/2018Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D- on 3/16/2018 due to a substantial increase in the efficiency index, growth index and valuation index. Net income increased 2,450.56% from -$2.06M to $48.45M, earnings per share increased from -$0.03 to $0.5792, and total capital increased 63.86% from $129.27M to $211.82M.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D- on 3/16/2018 due to a substantial increase in the efficiency index, growth index and valuation index. Net income increased 2,450.56% from -$2.06M to $48.45M, earnings per share increased from -$0.03 to $0.5792, and total capital increased 63.86% from $129.27M to $211.82M.
D
Sell
3/12/2018Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 3/12/2018 due to a decline in the valuation index and efficiency index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 3/12/2018 due to a decline in the valuation index and efficiency index.
D
Sell
8/10/2017Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 8/10/2017 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.4532 to -$0.2018, total capital increased 39.17% from $88.19M to $122.74M, and net income increased 38.49% from -$23.06M to -$14.19M.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 8/10/2017 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.4532 to -$0.2018, total capital increased 39.17% from $88.19M to $122.74M, and net income increased 38.49% from -$23.06M to -$14.19M.
D
Sell
5/10/2017Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 5/10/2017 due to a decline in the volatility index and total return index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 5/10/2017 due to a decline in the volatility index and total return index.
D
Sell
3/23/2017Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 3/23/2017 due to an increase in the growth index, efficiency index and volatility index. Total revenue increased 79.18% from $2.24M to $4.02M, total capital increased 71.25% from $78.14M to $133.82M, and operating cash flow increased 22.99% from -$21.77M to -$16.76M.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 3/23/2017 due to an increase in the growth index, efficiency index and volatility index. Total revenue increased 79.18% from $2.24M to $4.02M, total capital increased 71.25% from $78.14M to $133.82M, and operating cash flow increased 22.99% from -$21.77M to -$16.76M.
D
Sell
11/1/2016Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 11/1/2016 due to a decline in the volatility index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 11/1/2016 due to a decline in the volatility index.
D
Sell
10/17/2016Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 10/17/2016 due to an increase in the total return index, valuation index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D from D- on 10/17/2016 due to an increase in the total return index, valuation index and volatility index.
D
Sell
9/30/2016Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 9/30/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 144.42% from -$18.39M to -$44.95M, earnings per share declined from -$0.4844 to -$0.9667, and EBIT declined 22.13% from -$11.75M to -$14.36M.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D- from D on 9/30/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 144.42% from -$18.39M to -$44.95M, earnings per share declined from -$0.4844 to -$0.9667, and EBIT declined 22.13% from -$11.75M to -$14.36M.
D
Sell
3/11/2016Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
C
Hold
3/7/2016Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 3/7/2016 due to a major increase in the volatility index and valuation index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D+ on 3/7/2016 due to a major increase in the volatility index and valuation index.
D
Sell
12/29/2015Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 12/29/2015 due to a noticeable decline in the solvency index, total return index and volatility index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D+ from C- on 12/29/2015 due to a noticeable decline in the solvency index, total return index and volatility index.
C
Hold
11/17/2015Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D on 11/17/2015 due to an increase in the valuation index, efficiency index and solvency index. Total capital increased 52.97% from $102.74M to $157.15M, and debt to equity declined from 0.13 to 0.07.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to C- from D on 11/17/2015 due to an increase in the valuation index, efficiency index and solvency index. Total capital increased 52.97% from $102.74M to $157.15M, and debt to equity declined from 0.13 to 0.07.
D
Sell
5/28/2015Downgrade
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 5/28/2015 due to a decline in the volatility index and valuation index.
Sorrento Therapeutics, Inc. (SRNE) was downgraded to D from D+ on 5/28/2015 due to a decline in the volatility index and valuation index.
D
Sell
4/1/2015Upgraded
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D on 4/1/2015 due to a significant increase in the volatility index, total return index and valuation index.
Sorrento Therapeutics, Inc. (SRNE) was upgraded to D+ from D on 4/1/2015 due to a significant increase in the volatility index, total return index and valuation index.
OTC PK
04/11/2025 3:43PM Eastern
Quotes delayed
